Item 2.02 - Results of Operations and Financial Condition: The filing reports financial results and operational performance for BIO-TECHNE Corporation as of August 12, 2026 Item 8.01 - Other Events: The filing discloses additional material events or information relevant to shareholders that do not fit into other standard 8-K item categories Item 9.01 - Financial Statements and Exhibits: The…

Our analysis rates this filing BEARISH. Bio-Techne faces a HIGH concern environment driven by multiple material risk factors. The pending Merck KGaA acquisition at $11.3B dominates the risk landscape - while it provides a defined exit, regulatory and closing execution risks are substantial and…

Concern level: HIGH (7.6/10). Key factors: Pending $11.3B acquisition by Merck KGaA creates existential execution risk - deal failure would be catastrophic for shareholders and strategic direction; Zero organic revenue growth for full year FY2026 represents stagnation for a life sciences company, indicating structural market headwinds or competitive pressures; Adjusted EPS essentially flat YoY…

Notable risk changes: MAJOR: Bio-Techne agreed to be acquired by Merck KGaA for $73/share ($11.3B) - this is a transformational event with significant regulatory and closing execution risk. Shareholders are now dependent on deal completion.; MAJOR: Full year FY2026 organic revenue growth was 0% (flat) - this represents stagnation for a life sciences company and indicates underlying market weakness or competitive…

The model predicts TECH will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.